At a glance
- Note: These files are not yet 508
- Slides will be added as they become available.
February 28, 2024
Welcome & Introductions
Introduction
Dr. M Wharton
COVID-19 Vaccines
Dr. M Daley
COVID-19-associated hospitalizations among adults – COVID-NET [13 pages]
Dr. C Taylor
COVID-19 vaccination coverage update [27 pages]
Dr. K Chatham-Stephens
COVID-19 vaccine effectiveness [21 pages]
Dr. R Link-Gelles
Economic analysis of an additional dose of COVID-19 vaccine [24 pages]
Dr. L Prosser
Evidence to Recommendations [81 pages]
Dr. M Wallace
Next steps for the COVID-19 vaccine program [18 pages]
Dr. L Panagiotakopoulos
Chikungunya Vaccines
Dr. W Chen
Update on chikungunya vaccine licensure [6 pages]
Dr. S Hills
Dr. S Hills
Review of proposed policy options for chikungunya vaccine use among laboratory workers [7 pages]
Dr. S Hills
Vaccine use among pregnant and breastfeeding women [28 pages]
Dr. S Hills, Dr. D Meaney-Delman
DT Vaccine
Dr. M Hughes, Dr. J Santoli
Influenza Vaccines
Dr. J Loehr
Interim Estimates of 2023–24 Seasonal Influenza Vaccine Effectiveness [37 pages]
Dr. A Frutos
Dr. S Zhu
Safety of LAIV4 in Children with Asthma [18 pages]
Dr. B Creech
Influenza B/Yamagata Update [3 pages]
Dr. L Grohskopf
Polio Vaccines
Dr. O Brooks
Dr. S Kidd
Dr. S Kidd
February 29, 2024
Welcome & Introductions
Introduction
Dr. M Wharton
Respiratory syncytial virus (RSV) Vaccines Adults
Dr. C Kotton
Manufacturer presentation: Moderna safety & efficacy in adults aged ≥60 years [48 pages]
Dr. R Das
Risk-stratified rates of RSV-associated hospitalization among adults [26 pages]
Dr. R Woodruff
Implementation update: older adult RSV vaccination [30 pages]
Dr. C Black
Post-marketing safety surveillance of older adult RSV vaccination [34 pages]
Dr. T Shimabukuro
Dr. P Lloyd
Older adult RSV vaccination: benefits and risks discussion [33 pages]
Dr. M Melgar
Work group interpretations and discussion [41 pages]
Dr. A Britton
Meningococcal Vaccines
Dr. J Loehr
Dr. S Schillie
GSK Pentavalent MenABCWY vaccine: Term of Reference [10 pages]
Dr. S Schillie
Pneumococcal Vaccines
Dr. J Loehr
Mr. R Gierke
Dr. W Self
Phase 3 clinical trial data of PCV21 [37 pages]
Dr. H Platt
Post-licensure PCV20 safety data [19 pages]
Dr. P Moro
Safety Assessment of PCV20 [16 pages]
Dr. R Forshee
PCV21 Policy Questions and Preliminary WG interpretations of EtR [57 pages]
Dr. M Kobayashi
Combined Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae Type B Conjugate, and Hepatitis B vaccine (Vaxelis®)
Dr. J Loehr
Dr. J Collins
Dr. L Hammitt
Work group considerations [13 pages]
Dr. J Collins